Evidence map›Paper›PMID 28036291›Full record

ArticleOncotarget2017

Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis.

Nikolaos Kapodistrias, Konstantinos Mavridis, Anna Batistatou, Penelope Gogou, Vasilios Karavasilis, Ioannis Sainis, Evangelos Briasoulis, Andreas Scorilas

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. [The effect of miR-155 on HBV replication and PTEN expression in vivo].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018
    Article
  16. Article
  17. microRNAs Make the Call in Cancer Personalized Medicine.Frontiers in cell and developmental biology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Nikolaos KapodistriasCancer Biobank Center, University of Ioannina, University Campus, Ioannina, Greece.
Konstantinos MavridisDepartment of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Panepistimiopolis, Athens, Greece.
Anna BatistatouDepartment of Pathology, School of Medicine, University of Ioannina, Greece.
Penelope GogouClinical Oncology Department, Norwich University Hospital, UK.
Vasilios KaravasilisLondon Sarcoma Service, Department of Oncology, UCLH, London, UK.
Ioannis SainisCancer Biobank Center, University of Ioannina, University Campus, Ioannina, Greece.
Evangelos BriasoulisCancer Biobank Center, University of Ioannina, University Campus, Ioannina, Greece.
Andreas ScorilasDepartment of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Panepistimiopolis, Athens, Greece.
University of Ioannina · GRNational and Kapodistrian University of Athens · GRNorfolk and Norwich University Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liposarcoma (LPS) is a malignancy with extreme heterogeneity and thus optimization towards personalizing patient prognosis and treatment is essential. Here, we evaluated miR-155, miR-21, miR-143, miR-145 and miR-451 that are implicated in LPS, as novel FFPE tissue biomarkers.A total of 83 FFPE tissue specimens from primary LPS and lipomas (LPM) were analyzed. A proteinase K incubation-Trizol treatment coupled protocol was used for RNA isolation. After polyadenylation of total RNA and reverse transcription, expression analysis of 9 candidate reference and 5 target miRNAs was performed by qPCR. Genorm and NormFinder were used for finding the most suitable molecules for normalization. Survival analyses were performed in order to evaluate the prognostic potential of miRNAs.MiR-103 and miR-191 are most suitable for normalization of miRNA expression in LPS. MiR-155 and miR-21 are clearly overexpressed (P<0.001) in LPS compared with LPM specimens, whereas miR-145 (P<0.001), miR-143 (P =0.008) and miR-451 (P=0.037) are underexpressed. MiR-155 (P=0.007) and miR-21 (P=0.029) are differentially expressed between well-differentiated, dedifferentiated, myxoid/round cell and pleomorphic LPs tumor subtypes. MiR-155 represents a novel independent indicator of unfavorable prognosis in LPS (HR = 2.97, 95% CI = 1.23-7.17, P = 0.016).

Indexed as

Paraffin EmbeddingAdultAgedAged, 80 and overArea Under CurveBiomarkers, TumorDisease-Free SurvivalDisease ProgressionFemaleFixativesFormaldehydeGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateLipomaLiposarcomaBiomarkers, TumorFixativesFormaldehydeMicroRNAsMIRN155 microRNA, humanliposarcomamiR-155miRNA expression normalizationmiRNAsprognostic biomarker

Identifiers

PMID28036291
PMCPMC5351678
OpenAlexW2563900885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.